RTP Mobile Logo
Select Publications

Byrd JC et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res 2020;26(15):3918-27. Abstract

Fischer K et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: A prospective analysis of the randomized CLL14 trial. ASH 2019;Abstract 36.

Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016;127(2):208-15. Abstract

Hamblin TJ et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54. Abstract

Kazianka L et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017;31(5):1117-22. Abstract

Rossi D et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15(3):995-1004. Abstract

Shanafelt TD et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial. ASH 2019;Abstract 33.

Sharman JP et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 31.

Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019;133(12):1298-307. Abstract

Tedeschi A et al. Five-year follow-up of patients receiving ibrutinib for first-line treatment of chronic lymphocytic leukemia. EHA 2019;Abstract S107.

Thompson PA et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016;127(3):303-9. Abstract